Morgan Stanley keeps Buy rating on CSL stock at AUD 182.00

Published on 10/14/2026 at 09:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSL paid USD 355 million upfront on October 5, 2026. CSL stock trades at EUR 115.25 on October 14, 2026, with a EUR 115.02 bid.

Lixudebart deal sets development terms

CSL and Alentis announced a USD 355.00 million upfront payment on October 5, 2026.
The Phase 2 RENAL trial interim analysis covered 26 patients at 24 weeks.
CSL stock trades at EUR 115.25 at 9:11 a.m. CEST at Lang & Schwarz on October 14, 2026.

CSL, AU000000CSL8, Illustration mit AI erstellt.

Morgan Stanley maintained a Buy rating on CSL stock with an AUD 182.00 price target in a report dated October 11, 2026, according to Markets Insider. The more substantial operating event was CSL's October 5 agreement with Alentis Therapeutics to develop lixudebart for rare kidney and liver diseases, with an upfront payment of USD 355.00 million and potential milestones of up to USD 1.20 billion, as AAP reported.

Three dated strategic steps

CSL's recent sequence began on August 31, 2026, when the company announced agreements with the U.S. government supporting lower therapy prices and a USD 1.50 billion manufacturing expansion plan, according to CSL. On September 29, 2026, CSL announced a collaboration with Amazon Web Services to apply artificial intelligence and cloud technologies to biopharmaceutical research and development, the same CSL newsroom reported.

The latest strategic step arrived on October 5, 2026, with the Alentis partnership. CSL will fully fund the ongoing Phase 2 RENAL trial, a planned Phase 3 trial in AAV-RPGN, and Phase 2 studies in FSGS and PSC, while global profits would be shared 55 percent with CSL and 45 percent with Alentis, according to AAP.

What does the deal add?

The clinical evidence remains early. An interim analysis covered 26 patients with AAV-RPGN in the Phase 2 RENAL trial and reported improvement in kidney function at 24 weeks; a separate Phase 1b FEGATO study included 41 patients with advanced liver fibrosis and reported improved liver function at six weeks, according to BioPharm International. The same report noted that the interim RENAL findings were not peer-reviewed or published in full, making the 26-patient sample a material development risk.

CSL stock in morning trading

CSL stock was trading at EUR 115.25 at Lang & Schwarz on October 14, 2026 at 9:11 a.m. CEST. The quote showed a EUR 115.02 bid and a EUR 115.48 ask, while the primary ASX listing was last quoted at AUD 184.59 on October 14, 2026.

CSL's market capitalization was AUD 88.4 billion on October 14, 2026, and its 52-week range was AUD 90.00 to AUD 222.47. The current price therefore sits within a broad annual range, while the Alentis agreement adds a long-dated pipeline commitment rather than near-term revenue.

The further course of trading is shown by the continuously updated real-time quote of CSL stock.